GangaGen, Inc. is a biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as drug resistant bacteria such as MRSA and other drug-resistant pathogenic bacteria.
GangaGen Inc. was initially formed September 23, 2000 by CEO and founder Dr. J. Ramachandran in Bangalore, India, as GangaGen Biotechnologies Pvt Ltd (GBPL) to develop novel therapies for treating antibiotic-resistant infection. Based on the emerging opportunities for treating bacterial infection in the medical, veterinary, agricultural and environmental settings globally, and the interest of investors in the U.S. and Canada, GangaGen Inc was incorporated as a Delaware Corporation in August 2001.
GangaGen Inc. received permission from the Ministry of Commerce & Industry, Govt. of India on December 21, 2001 to convert GBPL into a fully owned subsidiary of GangaGen Inc.
The long-term objective of the Company is to commercially develop products to control multiple species of bacteria pathogenic to humans, particularly antibiotic-resistant strains. GangaGen's business strategy is to pursue specific human applications in areas of high unmet medical need.
The company’s lead product is a recombinant protein, P128, that binds to and kills Staphylococcus, including methicillin-resistant strains of S.aureus (MRSA).